KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $25.7 million.

  • Travere Therapeutics' Income from Continuing Operations rose 14694.99% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 7462.65%. This contributed to the annual value of -$320.6 million for FY2024, which is 1480.15% up from last year.
  • As of Q3 2025, Travere Therapeutics' Income from Continuing Operations stood at $25.7 million, which was up 14694.99% from -$12.8 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Income from Continuing Operations registered a high of $25.7 million during Q3 2025, and its lowest value of -$136.0 million during Q1 2024.
  • For the 5-year period, Travere Therapeutics' Income from Continuing Operations averaged around -$67.1 million, with its median value being -$80.0 million (2022).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 657439.9% in 2021, then skyrocketed by 14694.99% in 2025.
  • Over the past 5 years, Travere Therapeutics' Income from Continuing Operations (Quarter) stood at -$88.8 million in 2021, then increased by 3.53% to -$85.6 million in 2022, then decreased by 3.46% to -$88.6 million in 2023, then skyrocketed by 31.97% to -$60.3 million in 2024, then soared by 142.65% to $25.7 million in 2025.
  • Its Income from Continuing Operations was $25.7 million in Q3 2025, compared to -$12.8 million in Q2 2025 and -$41.2 million in Q1 2025.